Last updated on July 2019

A Study of the Anti-PD1 Antibody PDR001 in Combination With Dabrafenib and Trametinib in Advanced Melanoma


Brief description of study

To evaluate the safety and efficacy of the combination of an anti-PD-1 antibody (Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma

Clinical Study Identifier: NCT02967692

Find a site near you

Start Over

University of Missouri

Columbia, MO United States
  Connect »

Johns Hopkins U SC

Lutherville, MD United States
  Connect »

Highlands Oncology Group

Fayetteville, AR United States
  Connect »

UCSF

San Francisco, CA United States
  Connect »

California Pacific Medical Center

San Francisco, CA United States
  Connect »

Stanford Cancer Center SC-2

Stanford, CA United States
  Connect »

Utah Cancer Specialists SC-2

Salt Lake City, UT United States
  Connect »

Novartis Investigative Site

Boulogne Billancourt, France
  Connect »

Novartis Investigative Site

Chambray-lès-Tours, France
  Connect »

Novartis Investigative Site

Clermont Ferrand cedex 1, France
  Connect »

Novartis Investigative Site

Marseille Cedex 05, France
  Connect »

Novartis Investigative Site

Pierre Benite Cedex, France
  Connect »

Novartis Investigative Site

Vandoeuvre-les-Nancy cedex, France
  Connect »

Novartis Investigative Site

Guadalajara Jalisco, Mexico
  Connect »

Novartis Investigative Site

Chelyabinsk, Russian Federation
  Connect »

Novartis Investigative Site

Moscow, Russian Federation
  Connect »

Novartis Investigative Site

Nizhny Novgorod, Russian Federation
  Connect »

Novartis Investigative Site

Samara, Russian Federation
  Connect »

Novartis Investigative Site

St Petersburg, Russian Federation
  Connect »

Novartis Investigative Site

Las Palmas De Gran Canarias, Spain
  Connect »

Novartis Investigative Site

Northwood, United Kingdom
  Connect »

Novartis Investigative Site

Leicester, United Kingdom
  Connect »

Novartis Investigative Site

Manchester, United Kingdom
  Connect »

Novartis Investigative Site

Middlesborough, United Kingdom
  Connect »

Novartis Investigative Site

Chambray-lès-Tours, France
  Connect »

Novartis Investigative Site

Chambray-lès-Tours, France
  Connect »

Novartis Investigative Site

Chambray-lès-Tours, France
  Connect »

Novartis Investigative Site

Chambray-lès-Tours, France
  Connect »

Novartis Investigative Site

Chambray-lès-Tours, France
  Connect »

Novartis Investigative Site

Chambray-lès-Tours, France
  Connect »

Novartis Investigative Site

Chambray-lès-Tours, France
  Connect »

Novartis Investigative Site

Chambray-lès-Tours, France
  Connect »

Novartis Investigative Site

Chambray-lès-Tours, France
  Connect »